SBRT Followed by Neoadjuvant Immunochemotherapy in Resectable Stage II to III Non-small Cell Lung Cancer

NCT05319574 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

46

Enrollment

OTHER

Sponsor class

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

RADIATION: SBRT
DRUG: Tislelizumab

Sponsor

Sun Yat-sen University